Business Covid-19 – Novartis stops its study with hydroxychloroquine

Covid-19 – Novartis stops its study with hydroxychloroquine

-

Citing a lack of participants, the pharmaceutical group of the basel put an end to his trials with hydroxychloroquine to treat the new coronavirus.

Novartis will not continue his research on hydroxychloroquine. (KEYSTONE/Georgios Kefalas)

KEYSTONE

The pharmaceutical group of the basel Novartis has put an end to its clinical trial with hydroxychloroquine, to treat diseases induced by the novel coronavirus. It invokes a lack of participants.

The u.s. agency of the drug, the Food and Drug Administration (FDA) had approved the study in April. Some 440 patients infected with the virus and hospitalized were to participate in the testing.

But on Monday, it withdrew its approval for the use of hydroxychloroquine, an anti-malarial drug, explaining that the latest studies confirmed not support the hypothesis of efficacy against pulmonary diseases.

(TTY/NXP)

Published today in 02h16

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Latest news

Food and health stores may only work until 12:00 noon in Cumaná

Photo: TwitterEdwin Rojas, Governor of the Sucre state, ad that the food and health shops in Cumaná can only...

Third Bonus I will stay at home: Bono 380 soles CHECK with ID if you are a beneficiary of the second part yomequedoencasa.pe Bonus...

LINK Bonus I stay home 380 soles | As announced by the President of the Republic Martín Vizcarra,...

Must read

You might also likeRELATED
Recommended to you